The Big Pharma Giants Are Down
It's evident that big pharma giant Moderna (NASDAQ: MRNA) is going through troubled times. Worse, it's dragging other big Pharma giants with it.
Precious Njoku is a Financial Writer with extensive knowledge about the stock market.
2022-11-06 11:35

The reason for this fall is not farfetched. Moderna lowered its sales guidance for 2022, and the market reacted negatively to the news. First of all, it tumbled 9.1% in pre-market on Thursday. Although, the bulls took advantage of the opportunity and rode it up to close at $147.
The Big Pharma Giants Are Down
BioNTech (NASDAQ: BNTX) did a 2.6% on the uptrend on Friday. At the same time, Nonovax (NASDAQ: NVAX) maintained stability at $20.17. However, I think these big pharma are only riding on false waves. I see a downtrend very soon. The fundamentals of these companies support this. Well, for now, I'll limit the extent of this article to Moderna.

A Look into Moderna's Earning Report

Moderna's (NASDAQ: MRNA) earnings report for Q3 2022 spells doom for this pharma giant. They missed earnings by a mile. Honestly, I don't think Q4 would be any better. The expectation for Moderna in revenue from its Covid Vaccine was around $21 billion. However, they were forced to cut guidance to around $18 Billion. This is significant because a massive chunk of their sales came from Covid vaccines. Thus, lowering guidance on this would result in a decline in revenue and net profit margin. And this it did, as net income came at a 69% decrease compared with YoY for 2021. In addition, EPS also saw a decline of about 67% at $2.53 compared to the same period last.

The big question is: Would Moderna perform better next quarter?

The answer is no. For one, factors affecting the reduction in revenue still linger. A supply chain constraint pushed delivery of their Covid vaccine into the middle of next year, 2023. Also, the delivery of two new products from Moderna was put on hold, an omicron BA.5 and a BA.1 shot.

A buy Now for Moderna?

Absolutely not. The technical and fundamental aspects of this stock are not giving off any buy signal.

Fundamentally, Moderna would be down in cash for the next 3 straight quarters. By the time Covid 19 reaches its endemic phase, the massive demand for the vaccine will reduce drastically. Coupled with the already existing delivery constraint, I see a 70% reduction in revenue for Q4 2022, the same period as last year.

Technically, Moderna is also not forming any chat pattern. The stock is expected to move sideways for a while. In addition, the Relative Stock Index (RSI) for Moderna is 36. Moderna may be hovering in an overbought position if this metric dips further. So technically, it is not a stock to buy at the moment.

Except Moderna rolls out a wonder drug in the next 2 quarters, it's most likely they will go through a pronounced downtrend. Moderna has been one of the most rewarding stocks to ride through the Covid era. However, one must recognize the end of an era to the beginning of the next to make sound investment decisions.

Where lies the next golden opportunity in the market? Follow along as I show you.

Disclaimer: I have no positions in any of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article. All information should be independently verified and should not be relied upon for purposes of transacting securities or other investments. See terms for more info.

Rate this article

Published On
2022-11-06 11:35

About the Author
Precious Njoku is a Financial Writer with extensive knowledge about the stock market.

You've read 1 article in the last year
..thank you for supporting us and for visiting our site. Unlike many other sites, The Dog of Wall Street is available for everyone to read. Our focus is to provide great content for free. Do you like what we are doing? Buy us a cup coffee. It is the fuel that keeps us going..

2 Earnings Misses to Buy Now
Every quarter, there are always a few companies that are punished for their earnings.
By Mike Sakuraba | 3 weeks ago

2 Fintech Stocks to Buy After Impressive Earnings Calls
Here are two stocks that stood out to me as buying opportunities after their recent earnings calls.
By Mike Sakuraba | 4 weeks ago

Apple Earnings: Is the King Still the King?
But there might be signs that the king is losing a bit of his lustre.
By Mike Sakuraba | 4 weeks ago

Solar Stocks or EV Stocks? Which Am I Buying?
In a high-interest rate climate, both EV and solar stocks are underperforming, with major companies like Tesla and Enphase facing challenges, making neither an immediate attractive investment.
By Mike Sakuraba | 1 month ago

Big Tech Earnings Are In: What Did We Think?
If the market is ever going to reverse course it will be on the strength of big tech.
By Mike Sakuraba | 1 month ago

Can Big Tech Save the Markets Next Week?
Meta and Amazon Are My Top Picks.
By Mike Sakuraba | 1 month ago

Tesla Stock After Earnings: Something has Changed
What do we do with Tesla stock from here?
By Mike Sakuraba | 1 month ago

Is Palantir a Trillion Dollar Company?
Why do I think it can continue to grow into one of the largest companies in the world
By Mike Sakuraba | 1 month ago